Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial

Andreas Katsambas, Ketty Peris, Gino Vena, Peter Freidmann, Gottfried Wozel, Esteban Daudén, Daiana Licu, Mauro Placchi, Michel De La Brassinne, Andreas Katsambas, Ketty Peris, Gino Vena, Peter Freidmann, Gottfried Wozel, Esteban Daudén, Daiana Licu, Mauro Placchi, Michel De La Brassinne

Abstract

This post-approval, open-label trial (n = 1266) assessed the efficacy of efalizumab, administered in accordance with the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By Week 12, an improvement from baseline of 50% or more was observed in 21.4% (181/844) of patients with nail psoriasis, 62.4% (718/1150) of patients with scalp psoriasis, and 51.4% (127/247) of patients with palmoplantar psoriasis. Quality of life improved throughout the trial, with a 50% median improvement in DLQI score after 12 weeks of treatment. Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of life.

Figures

Figure 1
Figure 1
Proportions of patients achieving a 50% or 75% improvement from baseline to Week 12 in Nail Psoriasis Severity Index (NAPSI), Psoriasis Scalp Severity Index (PSSI), or Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) score; intent-to-treat populations.
Figure 2
Figure 2
Median (interquartile range) Dermatology Life Quality Index score (a) Weeks 0–12, intent-to-treat population; (b) Week 20, continuous-treatment population.

References

    1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(suppl 2):8–23.
    1. Larko O. Problem sites: Scalp, palm and sole, and nail. Dermatol Clin. 1995;13:771–7.
    1. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20:60–7.
    1. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. J Am Acad Dermatol. 2003;49:271–5.
    1. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol. 2006;33:1452–6.
    1. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2:159–65.
    1. Wozel G. Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448–59.
    1. Lotti T, Chimenti S, Katsambas A, Ortonne J-P, Dubertret L, Licu D, et al. Efficacy and safety of efalizumab in patients with moderate-to-severe plaque psoriasis resistant to previous anti-psoriatic treatment: Results of a multicentre, open-label, Phase IIIb/IV trial. Arch Drug Info. 2009 in press.
    1. Takahashi MD, Chouela EN, Dorantes GL, Roselino AM, Santamaria J, Allevato MA, et al. Efalizumab in the treatment of scalp, palmoplantar, and nail psoriasis: Results of a 24-week Latin American study. Arch Drug Info. 2009 in press.
    1. Leonardi C, Sofen H, Krell J, Caro I, Compton P, Sobell JM. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaque psoriasis. J Am Acad Dermatol. 2007;56:AB48.
    1. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003;290:3073–80.
    1. Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol. 1995;133:575–8.
    1. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31–8.
    1. Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139] BMC Dermatol. 2005;5:13.
    1. Wahl AK, Mørk C, Lillehol BM, Myrdal AM, Helland S, Hanestad BR, et al. Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology. Acta Derm Venereol. 2006;86:198–201.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner